

TECHNICAL MANUAL

FcγRIIb CHO-K1 Cells, Propagation Model

Instructions for Use of Product
J2232

FcγRIIb CHO-K1 Cells, Propagation Model

All technical literature is available at: www.promega.com/protocols/
 Visit the website to verify that you are using the most current version of this Technical Manual.
 Email Promega Technical Services if you have questions on use of this system: techserv@promega.com

1. Description	2
2. Product Components and Storage Conditions	8
3. Before You Begin	9
3.A. Materials to Be Supplied by the User	9
3.B. Preparing FcγRIIb CHO-K1 Cells	10
4. Example Assay Protocol for FcγRIIb-Dependent Antibodies Using 4-1BB Effector Cells	12
4.A. Preparing Assay Buffer, BioGlo™ Reagent and Antibody Samples	12
4.B. Plate Layout Design	14
4.C. Preparing and Plating FcγRIIb CHO-K1 Cells	14
4.D. Preparing Antibody Serial Dilutions	15
4.E. Preparing 4-1BB Effector Cells	16
4.F. Adding Antibody Samples and 4-1BB Effector Cells to Assay Plates	17
4.G. Adding Bio-Glo™ Reagent	17
4.H. Data Analysis	17
5. Troubleshooting	18
6. References	19
7. Appendix	20
7.A. Composition of Buffers and Solutions	20
8. Summary of Changes	20

1. Description

The human immune system is regulated by a complex network of inhibitory and stimulatory receptors that facilitate the elimination of pathogens, while maintaining tolerance to self-antigens. Stimulatory immune checkpoint receptors appear to have a significant role in cancer progression and autoimmune disease. Several costimulatory immune checkpoint receptors such as Glucocorticoid-induced tumor necrosis factor receptor (TNFR) family-related protein (GITR), 4-1BB (CD137/TNFRSF9), OX40 (CD134) and CD40 have been identified. Activating these receptors with agonist monoclonal antibodies has emerged to be a novel strategy to enhance anti-tumor immune responses and promote immune-mediated tumor rejection (1,2).

CD40 is a member of the TNFR superfamily expressed by B cells, dendritic cells, monocytes, normal cells and some malignant cells. CD40 agonists have been shown to rescue function of antigen presenting cells (APC) in tumor-bearing hosts and restore effective immune responses against tumor antigens.

4-1BB, a member of the TNFR superfamily, is an inducible costimulatory receptor expressed on T cells, natural killer (NK) cells and innate immune cell populations (3). When present on the cell surface, 4-1BB interacts with 4-1BB ligand and induces subsequent cell proliferation and production of interferon gamma (IFN γ) and interleukin-2 (IL-2), particularly in T and NK cells (4,5).

GITR is a member of the TNF receptor superfamily and can be modulated by agonist antibodies or natural ligand to serve as an effective anti-tumor therapy. Preclinical studies have demonstrated that signaling through GITR can enhance activation of T effector cells (Teff) and modulate the activity of intra-tumor T regulatory cells (Tregs) during immunotherapy.

OX40 is a member of the TNFR superfamily. OX40 signaling has also been shown to inhibit the production of IL-10 by suppressing the function of Treg cells. Preclinical studies have demonstrated that treatment of tumor bearing hosts with OX40 agonists, including both agonist antibody (Ab) and fusion proteins, results in T cell differentiation and cytolytic function leading to enhanced anti-tumor immunity against a variety of tumors. Multiple preclinical investigations have unveiled a new strategy of targeting multiple immune checkpoints with different mechanisms for improved anti-tumor responses in a variety of cancers (1).

Current methods used to measure the activity of biologic drugs targeting costimulatory immune checkpoint molecules rely on primary human T cells and measurement of functional endpoints such as cell proliferation, cell surface marker expression, and IFN γ and IL-2 production. These assays are laborious and highly variable due to their reliance on donor primary cells, complex assay protocols and unqualified assay reagents. As a result, these assays are difficult to establish in a drug-development setting.

The CD40 Bioassay, Propagation Model (Cat.# J2132), 4-1BB Bioassay, Propagation Model (Cat.# J2332), OX40 Bioassay and GITR Bioassay are bioluminescent cell-based assays that overcome the limitations of existing assays and can be used to measure the potency and stability of antibodies and other biologics targeting CD40, 4-1BB, OX40 and GITR, respectively (6, 7).

The antibodies used to stimulate T cell activation via interaction with costimulatory receptors on the effector cells can be cross-linked via binding to FcγRIIb receptors on CHO-K1 cells. This crosslinking increases avidity and stabilizes the interaction of the antibody to the receptor, in certain cases. Based on the properties of the antibody tested, the Costimulatory Immune Checkpoint (i.e., OX40, CD40, GITR and 4-1BB) bioassays can be conducted in a single genetically engineered cell system or dual genetically engineered cell systems:

- **FcγRIIb CHO-K1 Cells^(a-d)**: CHO-K1 cells engineered to express human FcγRIIb. The FcγRIIb CHO-K1 Cells are provided in Cell Propagation Model (CPM) format, which includes cryopreserved cells that can be thawed, propagated and banked for long-term use. These are not reporter cells, and function solely to crosslink anti-CD40, anti-OX40, anti-4-1BB or anti-GITR antibodies.

The Costimulatory Immune Checkpoint Bioassays (CD40, OX40, GITR or 4-1BB Bioassays), Propagation Model, reflect the mechanism of action (MOA) of biologics designed to activate CD40, OX40, GITR or 4-1BB, respectively. Specifically, CD40-, OX40-, GITR- or 4-1BB-mediated luminescence is detected following the addition of CD40, OX40, GITR or 4-1BB agonist antibodies or CD40, OX40, GITR or 4-1BB ligand, respectively. FcγRIIb CHO-K1 cells might be required to crosslink the antibodies but are not required for the ligands. It is recommended that while screening for agonist antibodies of costimulatory immune checkpoints, you should perform the assay both with and without FcγRIIb CHO-K1 cells to ascertain the need for these cells in enhancing the effect of the agonist antibodies raised against the costimulatory immune checkpoint targets (Figure 1).

The bioassays are prequalified according to ICH guidelines and show the precision, accuracy and linearity required for routine use in potency studies (Figures 2 and 3; Tables 1 and 2). The assay can be performed in a 1-day or 2-day time frame depending on antibody property. The bioassay workflow is simple and robust, and compatible with both 96- and 384-well plate formats used for antibody screening in early drug discovery (Figures 4 and 5). In addition, the bioassay can be used with up to 100% human serum (in antibody samples) with minimal impact on fold induction, indicating potential for further development into a neutralizing antibody bioassay.

1. Description (continued)




Figure 1. Representation of costimulatory bioassays (CD40, OX40, GTR or 4-1BB) with FcγRIIb-independent and FcγRIIb-dependent antibodies. Panel A. Assay with FcγRIIb-independent Antibody. The bioassay consists of one engineered cell line: CD40, OX40, GTR or 4-1BB Effector Cells. In the absence of agonist antibody or ligand, the CD40, OX40, GTR or 4-1BB receptor is not activated and luminescence signal is low. The addition of agonist antibody or ligand induces the CD40, OX40, GTR or 4-1BB pathway-activated luminescence, which can be detected in a dose-dependent manner by addition of Bio-Glo™ Reagent and quantitation with a luminometer. **Panel B.** Assay with FcγRIIb-dependent Antibody. The bioassay consists of two engineered cell lines: CD40, OX40, GTR or 4-1BB Effector Cells and FcγRIIb CHO-K1 Cells. In the presence of FcγRIIb CHO-K1 Cells, the anti-CD40, -OX40, -GTR or 4-1BB antibody is cross-linked, thereby inducing CD40, OX40, GTR or 4-1BB pathway-activated luminescence, which can be detected in a dose-dependent manner by addition of Bio-Glo™ Reagent and quantitation with a luminometer.




Figure 2. Using the CD40 Bioassay in the presence of FcγRIIb CHO-K1 Cells reflects the mechanism of action (MOA) and specificity of biologics designed to activate CD40 receptor. When incubated in the presence of FcγRIIb CHO-K1 Cells, CD40 Effector Cells were induced respectively with a serial titration of control antibodies: Anti-CD40, Anti-4-1BB, Anti-OX40 or Anti-GITR as indicated. Bio-Glo™ Reagent was added and luminescence was quantified using the GloMax® Discover System. Data were fitted to a 4-parameter logistic curve using GraphPad Prism® software. Data were generated using thaw-and-use cells.

Table 1. The CD40 Bioassay Shows Precision, Accuracy and Linearity.

Parameter	Results	
Accuracy	% Expected Relative Potency	% Recovery
	50	98.7
	70	99.8
	140	104.0
	200	100.8
Repeatability (% CV)	100% (Reference)	5.1
Intermediate Precision (% CV)		7.0
Linearity (r ²)		0.997
Linearity (y = mx + b)		y = 1.028X-0.0284
A 50–200% theoretical potency series of Control Ab, Anti-CD40, was analyzed in triplicate in three independent experiments performed on three days by two analysts. Bio-Glo™ Reagent was added and luminescence was quantified using the GloMax® Discover System. Data were analyzed and relative potencies were calculated after parallelism determination using JMP® software. Data were generated using thaw-and-use cells.		

1. Description (continued)




Figure 3. Using the 4-1BB Bioassay in the presence of FcγRIIb CHO-K1 Cells reflects the mechanism of action (MOA) and shows specificity of biologics designed to activate 4-1BB. When incubated in the presence of FcγRIIb CHO-K1 Cells, 4-1BB Effector Cells were induced respectively with a serial titration of control antibodies: Anti-4-1BB, Anti-OX40 or Anti-GITR as indicated. Bio-Glo™ Reagent was added and luminescence was quantified using the GloMax® Discover System. Data were fitted to a four-parameter logistic curve using GraphPad Prism® software. Data were generated using thaw-and-use cells.

Table 2. The 4-1BB Bioassay Shows Precision, Accuracy and Linearity.

Parameter	Results	
Accuracy	% Expected Relative Potency	% Recovery
	50	106.0
	70	96.2
	140	97.3
	200	103.2
Repeatability (% CV)	100% (Reference)	3.5
Intermediate Precision (% CV)		6.6
Linearity (r ²)		0.996
Linearity (y = mx + b)		y = 1.025X-1.835
A 50–200% theoretical potency series of Control Ab, Anti-4-1BB, was analyzed in triplicate in three independent experiments performed on three days by two analysts. Bio-Glo™ Reagent was added and luminescence was quantified using the GloMax® Discover System. Data were analyzed and relative potencies were calculated after parallelism determination using JMP® software. Data were generated using thaw-and-use cells.		




Figure 4. The assay is amenable to 384-well plate format and compatible with laboratory automation when using CD40 Effector Cells and FcγRIIb CHO-K1 Cells. The CD40 Bioassay was performed in the presence of FcγRIIb CHO-K1 cells using Control antibody, Anti-CD40, either in 96-well format (**Panel A**) or in 384-well format (**Panel B**) using a ThermoFisher Multidrop™ Combi nL Reagent Dispenser to dispense the cells and assay buffer and Echo® Acoustic liquid handler for antibody handling. On the day before the assay, CD40 effector cells were plated at 8×10^3 cells per 10µl/well. The next day, assay buffer was added to the plate at 5µl/well. The Control Ab, Anti-CD40, was dispensed in submicroliter volumes to the assay plate and serially titrated by direct dilution. Finally, FcγRIIb CHO-K1 cells were added at 10×10^3 cells per 5µl/well. After a 6-hour incubation, 20µl of Bio-Glo™ Reagent was added and luminescence was quantified using the GloMax® Discover System. Data were fitted to a four-parameter logistic curve using GraphPad Prism® software. The EC₅₀ values were 0.27µg/ml and 0.23µg/ml, and the fold inductions were 6.3 and 4.7 for 96- and 384-well format, respectively. Data were generated using thaw-and-use cells.

1. Description (continued)




Figure 5. The assay is amenable to 384-well plate format and compatible with laboratory automation when using 4-1BB Effector Cells and FcγRIIb CHO-K1 Cells. The 4-1BB Bioassay was performed in the presence of FcγRIIb CHO-K1 cells using Control Ab, Anti-4-1BB, either in 96- format (**Panel A**) or in 384-well format (**Panel B**) using a Mantis® liquid handler to dispense the cells and Echo® Acoustic liquid handler for antibody handling. On the day before the assay, FcγRIIb CHO-K1 Cells were plated at 8×10^3 cells per 10µl/well. The next day, Control Ab, Anti-4-1BB, was serially diluted and added to the plate at 0.2µl/well. Finally, 4-1BB Effector Cells were added at 1.0×10^4 cells per 10µl/well. After a 6-hour incubation, 20µl of Bio-Glo™ Reagent was added and luminescence was quantified using the GloMax® Discover System. Data were fitted to a four-parameter logistic curve using GraphPad Prism® software. The EC₅₀ values were 0.13µg/ml and 0.095µg/ml, and the fold inductions were 103 and 58 for 96- and 384-well format, respectively. Data were generated using thaw-and-use cells.

2. Product Components and Storage Conditions

PRODUCT	SIZE	CAT. #
FcγRIIb CHO-K1 Cells, Propagation Model	1 each	J2232

Not for Medical Diagnostic Use. Includes:

- 2 vials FcγRIIb CHO-K1 Cells (CPM), 12.8×10^6 cells/ml (1.0ml per vial)

Notes: Thaw and propagate one vial to create frozen cell banks before use in an assay. The second vial should be reserved for future use.

Storage Conditions: Upon arrival, immediately transfer the cell vials to below -140°C (freezer or liquid nitrogen vapor phase) for long-term storage. Do not store cell vials submerged in liquid nitrogen. **Do not** store cell vials at -80°C because this will decrease cell viability and cell performance.

3. Before You Begin

Please read through the entire protocol to become familiar with the components and the assay procedure before beginning.

Note the catalog number and lot number from the cell vial box label. This information can be used to download documents for the specified product from the website, such as the Certificate of Analysis.

The FcγRIIb CHO-K1 Cells, Propagation Model, are intended for use with user-provided antibodies or other biologics designed to activate target receptors. They can be used in conjunction with CD40 Effector Cells or 4-1BB Effector Cells, as described above, to detect agonist antibodies that require FcγRIIb crosslinking in order to activate the target receptor. Data generated using these reagents are shown in Figures 2–5, above.

Cell thawing, propagation and banking should be performed exactly as described in Section 3. Cell seeding and propagation densities have been optimized to ensure stable cell growth, which is reflected in a steady cell doubling rate, to achieve optimal, consistent performance. An accurate, reliable, and reproducible cell counting method is required for routine cell culturing and optimal bioassay performance. The recommended cell plating densities, induction time and assay buffer components described in Section 4 were established using Control Ab, Anti-4-1BB. You may need to adjust the parameters provided here and optimize assay conditions for your own antibody or biologic, depending on the costimulatory bioassay of interest.

The CD40 and 4-1BB Bioassays produce a bioluminescent signal and require a sensitive luminometer or luminescence plate reader for the detection of luminescence. Bioassay development and performance data included in this Technical Manual were generated using the GloMax® Discover System (see Section 7.B, Related Products). An integration time of 0.5 second/well was used for all readings.

3.A. Materials to Be Supplied by the User

(Composition of Buffers and Solutions is provided in Section 7.A.)

Reagents

- User-defined anti-4-1BB antibodies or other biologics
- Ham's F12 Medium with L-glutamine (e.g., GIBCO® Cat.# 11765-054)
- RPMI 1640 Medium with L-glutamine and HEPES (e.g., Corning® Cat.# 10-041-CV or GIBCO® Cat.# 22400-089)
- Fetal bovine serum (e.g., HyClone Cat.# SH300070.03 or GIBCO® Cat.# 16000044)
- Blasticidin S (e.g., Invitrogen Cat.# A11139-03)
- DMSO (e.g., Sigma Cat.# D2650)
- DPBS (e.g., GIBCO® Cat.# 14190)
- Accutase® solution (e.g., Sigma Cat.# A6964)
- Trypan blue solution (e.g., Sigma Cat.# T8154)
- Bio-Glo™ Luciferase Assay System (Cat.# G7940, G7941)

3.A. Materials to Be Supplied by the User (continued)

Supplies and Equipment

- white, flat-bottom 96-well assay plates (e.g., Corning® Cat.# 3917)
- T75 tissue culture flask (e.g., Corning® Cat.# CLS430641U)
- sterile, clear V-bottom 96-well plate with lid (e.g., Costar® Cat. Cat.# 3896 or Linbro Cat.# 76-223-05) for preparing antibody dilutions
- pipettes (single-channel and twelve-channel); for best results use both manual and electronic pipettes as needed
- sterile 15ml and 50ml conical tubes
- sterile reagent reservoirs (e.g., Corning® Cat.# 4870)
- 37°C, 5% CO₂ incubator
- 37°C water bath
- plate reader with glow luminescence measuring capability or luminometer (e.g., GloMax® Discover System or equivalent)

3.B. Preparing FcγRIIb CHO-K1 Cells

Cell Thawing and Initial Cell Culture

1. Prepare 70ml of initial cell culture medium by adding 7ml of FBS to 63ml of Ham's F12 medium prewarmed to 37°C. This initial cell culture medium will be used for culturing the cells immediately after thawing.
2. Transfer 9ml of pre-warmed initial cell culture medium to a 15ml conical tube.
3. Remove one vial of FcγRIIb CHO-K1 cells from storage at -140°C and thaw in a 37°C water bath with gentle agitation (no inversion) until just thawed (typically 2–3 minutes).
4. Transfer all of the cells (approximately 1ml) to the 15ml conical tube containing 9ml of prewarmed initial cell culture medium.
5. Centrifuge at 180 × *g* for 5 minutes.
6. Carefully aspirate the medium, and resuspend the cell pellet in 60ml of pre-warmed initial cell culture medium.
7. Transfer the cell suspension to either four T75 tissue culture flasks (15ml each) or two T150 tissue culture flasks (30ml each), and place the flask horizontally in a 37°C, 5% CO₂ incubator.
8. Incubate for approximately 48 hours before passaging the cells.

Cell Maintenance and Propagation

Note: For cell maintenance and propagation starting from the second cell passage, use the cell growth medium containing antibiotics and monitor cell viability and doubling rate during propagation. The cell growth rate will stabilize by 7–10 days post-thaw, at which time cell viability is typically >95%, and the average cell doubling rate is ~24 hours. Passage number should be recorded for each passage. In our experience, cells maintain their functionality for up to 25 passages if passaging is performed on a Monday-Wednesday-Friday schedule.

1. On the day of cell passage, aspirate the cell culture medium and wash the cells with DPBS.

2. Add 3ml of Accutase solution to each T75 flask and place in a 37°C, 5% CO₂ incubator for 5–7 minutes or until the cells round up and detach from the bottom of the flask.
3. Add 7ml of cell growth medium to each T75 flask. Transfer the cell suspension to a sterile 15ml or 50ml conical tube.
4. Count the cells by Trypan blue staining. We suggest seeding the cells at a density of 4×10^4 cells/cm² if passaging every 2 days (e.g., Monday-Wednesday or Wednesday-Friday) or 2×10^4 cells/cm² if passaging every 3 days (e.g., Friday-Monday).
5. Add an appropriate amount of cell growth medium to a new flask.
6. Transfer the appropriate volume of cell suspension to achieve the desired cell seeding density per area.
7. Place the flasks horizontally in a 37°C, 5% CO₂ incubator.

Cell Freezing and Banking

1. On the day of cell freezing, make fresh cell freezing medium and keep on ice.
2. Aspirate the cell culture medium and wash the cells with DPBS.
3. Add 3ml of Accutase solution to each T75 flask and place in a 37°C, 5% CO₂ incubator for 5–7 minutes or until the cells round up and detach from the bottom of the flask.
4. Add 7ml of cell growth medium to each T75 flask. Transfer the cell suspension to a sterile 15ml or 50ml conical tube.
5. Remove a sample for cell counting by Trypan blue staining. Calculate the volume of cell freezing medium needed based on desired cell freezing densities of 3×10^6 – 1×10^7 cells/ml.
6. Transfer the cell suspension to 50ml sterile conical tubes or larger sized centrifuge tubes, and centrifuge at $180 \times g$, 4°C, for 5–10 minutes.
7. Carefully aspirate the supernatant and avoid disturbing the cell pellet.
8. Gently resuspend the cell pellet in ice-cold cell freezing medium to a final cell density of 3×10^6 – 1×10^7 cells/ml. Combine the cell suspensions into a single tube and dispense into cryovials.
9. Freeze the cells using a controlled-rate freezer (preferred), or a Mr. Frosty® or a Styrofoam® rack in a –80°C freezer overnight. Transfer the vials to at or below –140°C for long-term storage.

4. Example Assay Protocol for FcγRIIb-Dependent Antibodies Using 4-1BB Effector Cells

This assay protocol requires two engineered cell lines: 4-1BB Effector Cells and FcγRIIb CHO-K1 Cells. The FcγRIIb CHO-K1 cells are provided in CPM and Thaw-and-Use format, and either format can be used in this assay. Refer to the respective Costimulatory Bioassay protocols when using Thaw-and-Use cells.

The procedure below illustrates the use of the 4-1BB Bioassay to test two FcγRIIb dependent antibody samples against a reference sample in a single assay run. Each test and reference antibody is run in triplicate, in a ten-point dilution series, in a single 96-well assay plate using the inner 60 wells. Other experimental and plate layouts are possible but may require further optimization.

Note: When preparing test and reference antibodies, choose an appropriate starting concentration and dilution scheme to achieve a full dose-response curve with proper upper and lower asymptotes and sufficient points on the slope. For reference, we use 10μg/ml as a starting concentration (1X) and three-fold serial dilution when testing Control Antibody, Anti-4-1BB.

4.A. Preparing Assay Buffer, BioGlo™ Reagent and Antibody Samples

1. **FcγRIIb CHO-K1 Cell Recovery Medium:** On the day before the assay, prepare 40ml of Cell Recovery medium (90% Ham's F-12/10% FBS) in a 50ml conical tube. Thaw the FBS overnight at 4°C or in a 37°C water bath on the day of use. Add 4ml of FBS to 36ml of Ham's F-12 medium. Mix well and warm to 37°C before use.
2. **Assay Buffer:** On the day of the assay, prepare an appropriate amount of assay buffer (99% RPMI 1640/1% FBS). Thaw the FBS overnight at 4°C or in a 37°C water bath on the day of use. Mix well and warm to 37°C before use. For reference, 30ml of assay buffer is typically sufficient for 120 wells in a 96-well assay format using the inner 60 wells.

Note: The recommended assay buffer contains 1% FBS. This concentration of FBS works well for the Control Ab, Anti-4-1BB, that we tested.

3. **Bio-Glo™ Reagent:** For reference, 10ml of Bio-Glo™ Reagent is sufficient to assay 120 wells in a 96-well assay format. Thaw the Bio-Glo™ Luciferase Assay Buffer at 4°C overnight or in a room temperature water bath on the day of the assay. Equilibrate the Bio-Glo™ Luciferase Assay Buffer to ambient temperature, protected from light.

Transfer all of the Bio-Glo™ Luciferase Assay Buffer into the amber bottle containing the Bio-Glo™ Luciferase Assay Substrate and mix by inversion until the Substrate is thoroughly dissolved. Equilibrate and store the reconstituted Bio-Glo™ Reagent at ambient temperature (22–25°C) protected from light before adding to assay plates.

If you are using a large (100ml) size of Bio-Glo™ Luciferase Assay System, dispense the reconstituted Bio-Glo™ Reagent into 10ml aliquots and store at –20°C for up to six weeks. Avoid repeated freeze-thaw cycles. On the day of the assay, thaw an appropriate amount of reconstituted Bio-Glo™ Reagent in a room temperature (22–25°C) water bath for at least 1–2 hours before use, protected from light. Approximate stability of Bio-Glo™ Reagent after reconstitution is an 18% loss of luminescence after 24 hours at ambient temperature.

4. **Test and Reference Samples:** Using assay buffer as the diluent, prepare starting dilutions (dilu1, 3X final concentration) of two test antibodies (180μl each) and one reference antibody (400μl) in 1.5ml tubes. Store the tubes containing antibody starting dilutions appropriately before making antibody serial dilutions.

Note: If you are using Control Ab, Anti-4-1BB, as a reference antibody in your assay, prepare 400µl starting dilution with 30µg/ml Anti-4-1BB antibody (dilu1, 3X final concentration) by adding 12µl of anti-4-1BB, stock (1000 µg/ml) to 388µl of assay buffer. Store the antibody starting dilution on ice until ready to use in the assay.

Tip: To streamline assay setup, prepare antibody serial dilutions prior to harvesting and plating 4-1BB Effector cells.




Figure 6. Costimulatory Bioassay (CD40, OX40, 4-1BB or GITR) schematic protocol for FcγRIIb-dependent antibody. The addition of Effector Cells and FcγRIIb CHO-K1 cells may differ in order for certain bioassays. Refer to the appropriate Bioassay CPM Technical Literature for specific instructions.

4.B. Plate Layout Design

For the protocol described here, use the plate layout illustrated in Figure 7 as a guide. The protocol describes serial replicate dilutions ($n = 3$) of test and reference antibody to generate two ten-point dose-response curves for each plate.

Recommended Plate Layout Design													
	1	2	3	4	5	6	7	8	9	10	11	12	
A	B	B	B	B	B	B	B	B	B	B	B	B	Assay Buffer (B)
B	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ab
C	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
D	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ab
E	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
F	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Reference Ab
G	B	no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1	B	Test Ab
H	B	B	B	B	B	B	B	B	B	B	B	B	Assay Buffer (B)

Figure 7. Example plate layout showing non-clustered sample locations of test and reference antibody dilution series and wells containing assay buffer alone (denoted by “B”).

4.C. Preparing and Plating FcγRIIb CHO-K1 Cells

While maintaining the FcγRIIb CHO-K1 Cells (Cat.# J2232), follow the recommended cell seeding density. Changes in cell culture volume or seeding density will affect cell growth rate and assay performance. Do not allow the cells to grow to 100% confluence. Only use the cells in the assay after the cell doubling rate has stabilized during propagation.



Note: Perform the following steps in a sterile cell culture hood.

1. We recommend passaging the FcγRIIb CHO-K1 Cells 2 days before plating for the assay, as described above, to ensure optimal and consistent assay performance.
2. On the day before performing the assay, prepare cell recovery medium (Ham's F-12/10% FBS) for the FcγRIIb CHO-K1 Cells.
3. Aspirate the cell culture medium from the FcγRIIb CHO-K1 Cells and wash with DPBS.

4. Add 3ml of Accutase® solution to each T75 flask, and place the flask in a 37°C, 5% CO₂ incubator for 5–7 minutes or until the cells round up and detach from the bottom of the flask.
5. Add 7ml of FcγRIIb CHO-K1 cell recovery medium to the flask. Transfer the cell suspension to a 50ml (or larger) conical centrifuge tube.
6. Gently mix and count the FcγRIIb CHO-K1 Cells by Trypan blue staining.
7. Centrifuge at 230 × *g* for 10 minutes.
8. Gently resuspend the cell pellet in cell recovery medium to achieve a concentration of 4 × 10⁵ viable cells/ml.
9. Transfer the suspension to a sterile reagent reservoir. Using a multichannel pipette, immediately dispense 100μl of the cell suspension to each of the inner 60 wells of a 96-well white flat-bottom assay plate. The final cell number in each well should be 4 × 10⁴ cells/well.
10. Add 100μl of cell recovery medium to each of the outside wells of the assay plates.
11. Place lids on the assay plates and incubate in a 37°C, 5% CO₂ incubator overnight (18–22 hours).

4.D. Preparing Antibody Serial Dilutions

The instructions described here are for preparation of a single stock of 3-fold serial dilutions of a single antibody for analysis in triplicate (120μl of each antibody dilution provides a sufficient volume for analysis in triplicate). Alternatively, you can prepare three independent stocks of serial dilutions to generate triplicate samples. To prepare three-fold serial dilutions, you will need 400μl of reference antibody at 3X the highest antibody concentration in your dose-response curve. You will need 180μl of each test antibody at 3X the highest antibody concentration for test antibody dose-response curves. For other dilution schemes, adjust the volumes accordingly.

Note: If you are using Control Ab, Anti-4-1BB, as a control in the assay, follow the instructions below to prepare threefold serial dilutions. A threefold serial dilution for test antibodies was listed as an example below as well.

1. On the day of assay, prepare an appropriate amount of assay buffer as described in Section 4.A.
2. To a sterile, clear V-bottom 96-well plate, add 180μl of reference antibody starting dilution (dilu1, 3X final concentration) to wells A11 and B11 (see Figure 8).
3. Add 180μl of test antibodies 1 and 2 starting dilution (dilu1, 3X final concentration) to wells E11 and G11, respectively (see Figure 8).
4. Add 120μl of assay buffer to other wells in these four rows, from column 10 to column 2.
5. Transfer 60μl of the antibody starting dilutions from column 11 into column 10. Mix well by pipetting. Avoid creating bubbles.
6. Repeat equivalent threefold serial dilutions across the columns from right to left through column 3. Do not dilute into column 2.
7. Cover the assay plate with a lid and keep at ambient temperature (22–25°C) while preparing the 4-1BB Effector Cells.

Note: Wells A2, B2, E2 and G2 contain 120μl of assay buffer without antibody as a negative control.

Recommended Plate Layout for Antibody Dilutions Prepared from a Single Antibody Stock													
	1	2	3	4	5	6	7	8	9	10	11	12	
A		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Reference Ab
B		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Reference Ab
C													
D													
E		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Test Ab 1
F													
G		no Ab	dilu9	dilu8	dilu7	dilu6	dilu5	dilu4	dilu3	dilu2	dilu1		Test Ab 2
H													

Figure 8. Example plate layout showing antibody serial dilutions.

4.E. Preparing 4-1BB Effector Cells

While maintaining the 4-1BB Effector Cells, it is important to follow the recommended cell seeding density. Changes in cell culture volume or seeding density will affect cell growth rate and assay performance. Only use the cells in the assay after the cell doubling rate has stabilized during propagation. For more information on cell seeding density, please refer to the *4-1BB Bioassay, Cell Propagation Model, Technical Manual #TM551*.

Note: Passaging cells less than 40 hours before the assay is not recommended for this specific assay.

1. Passage the cells two days or three days before performing the assay to ensure optimal and consistent assay performance, maintain the cell density, upon harvest, in the range of $1.5\text{--}2.0 \times 10^6$ cells/ml and cell viability at greater than 90%.
2. Count the 4-1BB Effector Cells by Trypan blue staining, and calculate the cell density and viability.
3. Transfer an appropriate amount of 4-1BB Effector Cells from the culture vessel to a 50ml conical tube or larger sized centrifuge tube.
4. Collect the cells at $130 \times g$ for 10 minutes at ambient temperature and resuspend the pellet in assay buffer to generate the targeted cell density of 1×10^6 cells/ml.
5. You will need at least 8ml of 4-1BB Effector Cells to fill 120 assay wells, or the inner 60 wells of two assay plates.

4.F. Adding Antibody Samples and 4-1BB Effector Cells to Assay Plates

1. Take the 96-well assay plates containing FcγRIIb CHO-K1 Cells out of the incubator. Using a manual multichannel pipette, remove 95μl of medium from each of the wells. Alternatively, invert the assay plate above a sink to remove the medium. Then, place the inverted plate on paper towels for 5–10 seconds to drain any remaining medium.
2. Using an electronic multichannel pipette, add 25μl of the appropriate antibody titration to the assay plates according to the plate layout in Figure 7.
3. Add 75μl of assay buffer to the outside wells of the 96-well assay plates.
4. Transfer the 4-1BB Effector Cells prepared in Section 4.E to a sterile reagent reservoir. Using a multichannel pipette, dispense 50μl (0.5×10^5 cells) of 4-1BB Effector Cells into the wells containing antibody or ligand.
5. Cover the assay plates with lids and incubate in a 37°C, 5% CO₂ incubator for 6 hours.

4.G. Adding Bio-Glo™ Reagent

Note: Bio-Glo™ Reagent should be at ambient temperature (22–25°C) when added to assay plates.

1. Take the assay plates out from the incubator and equilibrate to ambient temperature for 10–15 minutes.
2. Using a manual multichannel pipette, add 75μl of Bio-Glo™ Reagent to the inner 60 wells of the assay plates, taking care not to create bubbles.
3. Add 75μl of Bio-Glo™ Reagent to wells B1, C1 and D1 of each assay plate to measure the background signal.
4. Incubate at ambient temperature for 5–15 minutes.
Note: Varying the incubation time will affect the raw relative light unit (RLU) values but should not significantly change the EC₅₀ value and fold induction.
5. Measure luminescence using a luminometer or luminescence plate reader.

4.H. Data Analysis

1. Determine the plate background by calculating the average RLU from wells B1, C1 and D1.
2. Calculate fold induction =
$$\frac{\text{RLU (induced-background)}}{\text{RLU (no antibody control-background)}}$$
3. Graph data as RLU versus Log₁₀ [antibody] and fold induction versus Log₁₀ [antibody]. Fit curves and determine the EC₅₀ value of antibody response using appropriate curve fitting software (such as GraphPad Prism® software).



5. Troubleshooting

For questions not addressed here, please contact your local Promega Branch Office or Distributor. Contact information available at: www.promega.com. Email: techserv@promega.com

Symptoms	Causes and Comments
Low luminescence measurements (RLU readout)	Choose an instrument designed for plate-reading luminescence detection. Instruments designed primarily for fluorescence detection are not recommended. Luminometers measure and report luminescence as relative values, and actual RLU numbers will vary between instruments. Some older models of luminometers with low sensitivity should be avoided. We recommend using a high gain setting if you are using a luminometer with an adjustable gain.
	Insufficient cells per well can lead to low RLU. Handle and plate the cells according to the instructions to ensure a sufficient number of viable cells per well.
	Low activity of Bio-Glo™ Reagent leads to low RLU. Store and handle the Bio-Glo™ Reagent according to the instructions. We recommend using Accutase for dissociation of FcγRIIb CHO-K1 cells prior to plating for Bioassays. Use of other dissociation methods (e.g., Trypsin) may result in lower RLU values due to loss of FcγRIIb receptors expressed on the CHO-K1 cell surface.
Variability in assay performance	Assay performance can be affected by variations in cell growth conditions including plating and harvest density, centrifuge times and speeds, and freezing and/or DMSO exposure times during cell banking.
	Poor cell viability and variations in doubling time may affect assay performance. Ensure consistent cell growth by handling the cells exactly according to the instructions. Avoid one-day cell passages whenever possible.
	Ensure you are using high-quality cell culture reagents (especially serum) and plastic ware for maintaining cells in culture. Ensure accurate and consistent cell counting methods.

Symptoms	Causes and Comments
Weak assay response (low fold induction)	Optimize the concentration range of your test sample(s) to achieve a full dose response with complete upper and lower asymptotes. The EC₅₀ value obtained in the CD40 Bioassay or 4-1BB Bioassay may vary from the EC₅₀ obtained using other methods. If untreated control RLU is less than 100-fold above plate reader background RLU, subtract plate reader background RLU from all samples prior to calculating fold induction.

6. References

1. Mahoney, K.M., Rennert, P.D. and Freeman, G.J. (2015) Combination cancer immunotherapy and new immunomodulatory targets. *Nat. Rev. Drug Discov.* **14**, 561–84.
2. Melero, I. *et al.* (2015) Evolving synergistic combinations of targeted immunotherapies to combat cancer. *Nat. Rev. Cancer.* **15**, 457–72.
3. Chester, C., Ambulkar, S. and Khort, H.E. (2016) 4-1BB agonism: adding the accelerator to cancer immunotherapy. *Cancer Immunol. Immunother.* **65**, 1243–8
4. Lee, H.W. *et al.* (2002) 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. *J. Immunol.* **169**, 4882–8.
5. Snell, L.M. *et al.* (2011) T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. *Immunol. Rev.* **244**, 197–217.
6. Grailer, J.J. *et al.* (2017) Quantitative cell-based bioassays to advance individual or combination immune checkpoint immunotherapy. *American Association for Cancer Research Annual Meeting*, Poster #5610.
7. Cheng, Z.J. *et al.* (2016) Bioassays power combination immunotherapy. *Genetic Engineering & Biotechnology News.* **36**, 9.

7. Appendix

7.A. Composition of Buffers and Solutions

initial cell culture medium for FCyRIIb CHO-K1 Cells

90% Ham's F12 with L-glutamine
10% FBS

cell growth medium for FCyRIIb CHO-K1 Cells

90% Ham's F12 with L-glutamine
10% FBS
10µg/ml Blasticidin S

cell freezing medium for FCyRIIb CHO-K1 Cells

85% Ham's F12 with L-glutamine
10% FBS
5% DMSO

cell recovery medium for FCyRIIb CHO-K1 Cells

90% Ham's F12 with L-glutamine
10% FBS

assay buffer

99% RPMI 1640 with L-glutamine
1% FBS

8. Summary of Changes

The following changes were made to the 6/26 revision of this document:

1. Removed Section 7.B, Related Products.
2. Made minor text and formatting edits.

^(a)NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.

This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use; (2) discovery, development and monitoring of biologic drugs and vaccines; (3) quality assurance testing of biologic drugs and vaccines; and (4) product release assays for biologic drugs and vaccines. No other commercial use is allowed. "Commercial use" means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to modify, derivatize, genetically engineer or otherwise create variations of the cells or genes stably transfected within the cells except that recipient may propagate and store the cells for long-term use. In addition, recipient must use luminescent assay reagents purchased from Promega for all luminescence-based assays using this product, or contact Promega to obtain a license for use of this product with reagents other than Promega's. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.

^(b)NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.

This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use, (2) discovery, development and monitoring of biologic drugs and vaccines, (3) quality assurance testing of biologic drugs and vaccines, and (4) product release assays for biologic drugs and vaccines. No other commercial use is allowed. "Commercial use" means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to modify, derivatize, genetically engineer or otherwise create variations of the cells or genes stably transfected within the cells except that recipient may propagate and store the cells for long-term use. In addition, recipient must use Bio-Glo™ Luciferase Assay System purchased from Promega Corporation for all luminescence assays using this product or contact Promega to obtain a license for use of this product with reagents other than Promega's. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.

^(c)U.S. Pat. No. 8,008,006.

^(d)Patent Pending.

© 2019–2026 Promega Corporation. All Rights Reserved.

GloMax and Lumit are registered trademarks of Promega Corporation. Bio-Glo is a trademark of Promega Corporation.

Accutase is a registered trademark of Innovative Cell Technologies Corporation. Echo is a registered trademark of Labcyte, Inc. Corning and Costar are registered trademarks of Corning, Inc. GIBCO is a registered trademark of Life Technologies Corporation. GraphPad Prism is a registered trademark of GraphPad Software, Inc. JMP is a registered trademark of SAS Institute, Inc. Mantis is a registered trademark of FORMULATRIX, Inc. Mr. Frosty is a registered trademark of Nalge Nunc International Corporation. Multidrop is a trademark of Thermo Fisher Scientific, Ltd. Styrofoam is a registered trademark of Dow Chemical Company.

Products may be covered by pending or issued patents or may have certain limitations. Please visit our website for more information.

All prices and specifications are subject to change without prior notice.

Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the most up-to-date information on Promega products.